Amgen s experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday.
Amgen Inc's experimental obesity drug showed promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday (Dec 3). The small Phase I trial found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected.
Amgen s experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday.
Amgen Inc s experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data
By Deena Beasley LOS ANGELES (Reuters) - Amgen Inc's experimental obesity drug demonstrated promising durability trends in an early trial, paving the .